← Insider buys

Johnny D Powers has bought stock on 4 days since Nov 2021

Director at Zomedica Corp., and 1 other company

SEC CIK 0001134545 · Filings on SEC.gov ↗

$234KBought
$1.1MSold
May 14Last buy

Johnny D Powers's record

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Companies

Every filing

7 filings since Apr 2021, newest first

About Johnny D Powers

Johnny D. Powers

Johnny D. Powers, BA, MS, PhD, MBA, is an accomplished executive with over 30 years of experience in business strategy, operations, sales, marketing, and product development in the human and pet medical diagnostics sectors.( He held senior roles at IDEXX Laboratories, Inc., serving as Executive Vice President from 2012 to 2016, overseeing business performance, product innovation, and commercial effectiveness across point-of-care and reference laboratory operations before retiring in May 2016.( His career also includes positions such as Vice President of Cancer Diagnostics at Becton, Dickinson & Co. (2008), President of TriPath Oncology, Inc. (2004-2007), Vice President & GM of Manufacturing Operations at Ventana Medical Systems, Inc. (2001), and Director at Organon Teknika Corp. LLC (1996).( Powers founded JD Powers Consulting Group, providing strategic advisory services in healthcare.(

Since August 2019, Powers has served as an Independent Director on the Board of Directors of Zomedica Corp. (ZOMDF), also sitting on the audit, compensation, and corporate governance committees.( As of 2025, he holds approximately 3.425 million shares valued at over $133,000, representing 0.35% ownership.( Powers earned a bachelor's degree in chemistry from Wake Forest University (1983), an M.S. in chemical engineering from Clemson University (1985), a Ph.D. in biochemical engineering from North Carolina State University (1989), and an M.B.A. from Duke University's Fuqua School of Business (1996).(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.